Sputum liquefiers

One hundred years of chronic obstructive pulmonary disease (COPD)

“…Several papers on the use of mucolytics agents in COPD were published. [210][211][212][213][214][215][216][217] In particular, Millar et al 213 were unable to find significant differences in lung function, mucociliary clearance curves or sputum viscosity following treatment with N-acetylcysteine (NAC) compared to control or placebo measurements. Even more important, Parr and Huitson 214 failed to find any statistically significant difference in the number of exacerbations between NAC or placebo groups after a 6-month treatment, although there was a slight trend towards improvement in the NAC group during the first 3 months of the trial.…”

The Evaluation of Mucolytic Drugs in Chronic Bronchitis

“…Palmer 29 has emphasized the importance of assisted postural coughing in patients with bronchitis and the response to physiotherapy in both chronic bronchitis and cystic fibrosis might be affected by an effective mucolytic.…”

Clinical experience of ‘Bisolvon’ in 220 cases of Chest Disease

“…Many forms of therapy have been tried in an attempt to improve, or assist the action of antibiotics which are the standard method of treatment in both bronchitis and pneumonia. Of particular interest was sputum thinning agents of which many have been tried but until recently no convincing evidence had been obtained of the value of any of these (Palmer 1966). One of the major drawbacks in examining and trying sputum thinning agents is the great difficulties encountered in assessing their effect on the patient.…”